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GENERIC PRESCRIPTION MEDICINES PRICEVARIATION
AMONG COMMUNITY PHARMACIES, PUBLIC HOSPITAL
PHARMACIES AND DISPENSING DOCTORS IN ZIMBABWE
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Zimbabwe, Harare, Zimbabwe
OBJECTIVES: To evaluate generic medicine price variation
among private retail pharmacies, public hospital pharmacies and
dispensing doctors in institutions in different provinces in Zim-
babwe. To compare prices of drugs on the Essential drugs list of
Zimbabwe (EDLIZ) and those not on the list and prices of
imported versus locally produced medicines. METHODS: Using
a standardized WHO and Health Action International (HAI)
methodology and data collection form, we collected medicine
price data for 58 institutions (comprising 27 community phar-
macies, eight public pharmacies and 23 dispensing doctors) on
37 carefully selected and commonly used generic medicines. At
each institution, we identiﬁed and recorded the price of the least
price generic medicine. The study was done in ﬁve of the ten
provinces in the country. We used a computerised WHO/HAI
International Medicine Price Workbook for data analysis.
RESULTS: Of the 37 generic medications, 18 and 22 were
signiﬁcantly expensive in dispensing doctors than in community
pharmacies and public hospital pharmacies respectively
(p < 0.05). Price of generic medications were not signiﬁcantly
different across provinces (p > 0.05). EDLIZ drugs had higher
overall mean prices than non-EDLIZ drugs (t = 2.274, df = 35;
p = 0.029). This was true in all the three sectors surveyed. There
was no signiﬁcant difference in overall mean drug prices between
locally produced medicines and imported medicines (t = -1.313;
df = 34; p = 0.197). Medications with high prices in the private
sector also had high prices in the public sector (r = 0.98,
p < 0.001). CONCLUSION: Zimbabwean generic medications’
prices are high and vary widely across sectors and by status of the
drug (EDLIZ vs. non-EDLIZ drugs). This may have differential
impacts on affordability and clinical outcomes.
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PREFERENCES FOR DRUG REIMBURSEMENT CRITERIA IN
SOUTH KOREA USING DISCRETE CHOICE EXPERIMENTS
Lim MK, Bae EY
Health Insurance Review Agency, Seoul, Seocho-Gu, South Korea
OBJECTIVES: The purpose of this study was to elicit preferences
for drug listing decision criteria in South Korea using the discrete
choice experiment (DCE) method. METHODS: A DCE survey
questionnaire was administered to a sample of respondents who
were educated in the principle concepts of pharmacoeconomics
and are decision makers or stakeholders within that ﬁeld. To
develop choice designs, we ﬁrst decided on the attributes and
levels through literature review and discussion with experts who
are involved in the decision making process. Then orthogonal
and balanced designs were determined using a computer algo-
rithm. A total of 15 choice sets were produced from the afore-
mentioned process. With the addition of 2 test questions, subjects
were shown a total of 17 sets of drugs with different levels of
ICER, uncertainty, budget impact, and severity of disease. We
used the conditional logit model to assess the effects of each
attribute. RESULTS: Parameter estimates from the model indi-
cate that all attributes inﬂuenced respondent’s choice signiﬁ-
cantly and each parameter has an expected sign. The Lower the
ICER, the higher the probability of choosing that alternative.
Respondents also preferred low levels of uncertainty and a
smaller impact on health service budget, and were likely to
choose drugs for serious diseases rather than mild or moderate
ones. We also found that those in our sample were willing to
accept high ICER to get medication for severe diseases. CON-
CLUSION: This study demonstrates that the cost-effectiveness,
budget impact and severity of disease are the main reimburse-
ment decision criteria in South Korea, and that DCE can be a
useful tool in analyzing the decision making process where a
variety of factors are considered and prioritized.
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OBJECTIVES: The objective of this study was to gather infor-
mation from individuals involved in the decision-making process
for determining the value of health care interventions.
METHODS: In April 2007, health care decision makers from
organizations across the US were invited to participate in a focus
group discussion. Prior to the focus group, participants com-
pleted a questionnaire, which inquired about the challenges
and/or opportunities associated with using health economic and
outcomes research information in the decision-making process.
RESULTS: Nine individuals with an average of over 14 years
experience, representing major managed care and pharmacy
beneﬁt management organizations, the Veteran’s Affairs Depart-
ment, and Academia participated. The three most challenging
issues to health care decision makers included: 1) ﬁltering
through all the information needed to determine value; 2) agree-
ing with the key assumptions used in models and/or research
reports; and 3) accepting model projections as an accurate reﬂec-
tion of outcomes that may be seen in their own patient popula-
tions. Findings revealed that decision makers are looking for
more customization, more applicability to their own organiza-
tions, and increased transparency when reviewing outcomes
research and/or health economic models. Other key ﬁndings
included, decision maker interest in being involved in the devel-
opment of tools and models from early phases, maximizing the
user-friendly aspect of models (without compromising transpar-
ency), development of tools that help decision makers analyze
real-world data, and the need for education and training as an
essential component of successful implementation of health eco-
nomic models and tools. CONCLUSION: This investigation
gives critical insight into how future health economic and out-
comes research models and data analysis tools should be devel-
oped. As payer needs continue to evolve, so must the models and
analysis tools that are developed, especially if they are expected
to continue to be used in the decision-making process.
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OBJECTIVES: There is increased interest in post-launch eco-
nomic studies as more jurisdictions require economic data for the
formal decision process of pricing and reimbursement of drugs.
METHODS: We reviewed all of the ﬁnal recommendations
regarding all pharmaceutical submissions to the CDR from its
inception in May 2004 through January 2007. Decisions were
categorised as: listed, listed with criteria or not listed. Recom-
mendations for further research post-launch were reviewed and
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categorized regarding the speciﬁcs of the type of data requested.
Using a comparative framework to examine the recommenda-
tions of CDR and NICE, we describe the frequency of the dif-
ferent types of data recommended for collection post-launch to
highlight trends across jurisdictions RESULTS: Thirty-four of 64
CDR submissions recommended ‘no listing’, 17 ‘list with crite-
ria’, and 13 ‘list or list in similar manner as other drugs in the
same category’. Of the 64 appraisals, 41 were recommended to
conduct further research to either collect speciﬁc items of data
(n = 28), conduct subgroup analysis (n = 13), or collect data
using a more appropriate study design (n = 19). The most com-
monly requested item was long-term adverse events or safety
data (16/28), and this observation is consistent with the fact that,
to date, most post-launch studies are safety surveillance studies.
In addition 11 of 28 recommended the collection of clinically
important outcomes, long-term effectiveness (7/28). Similarly, 41
of 48 NICE appraisals recommended further research to collect
real-world data, including treatment pathways, effectiveness, and
long-term effectiveness or adverse events. CONCLUSION: This
review suggests that recommendations for post-launch research
from CDR and NICE appear to be similar. This highlights the
inherent weakness of regulatory trials as a piece of evidence in
informing reimbursement decisions.
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HEALTH CARE DECISION-MAKERS’ ATTITUDE ON HEALTH
ECONOMICS RESEARCH
Galani Berardo C
Institute for Medical Technology Assessment, Erasmus MC, Rotterdam,
The Netherlands
OBJECTIVE: To assess lifetime cost-effectiveness of glatiramer
acetate (GA) compared to natalizumab (NZ) in patients diag-
nosed with relapsing-remitting multiple sclerosis (RRMS) in
the presence of long-term clinical evidence. METHODS: A
literature-based Markov model was developed with patients
transitioning through health-states based on Kurtzke expanded
disability status scale (EDSS). Patients in the model are21 years
of age with RRMS and start in any of the health-states at diag-
nosis. Patients with an EDSS score below 6.0 receive treatment.
Treatment effects for relapse and disease progression were
obtained from clinical trials and long-term clinical evidence
where available. Transition rates were estimated by applying a
percent reduction of treatment effects of therapies to natural
history rates of relapse and disease progression. Rates were
adjusted for treatment discontinuation and persistent NZ anti-
bodies. Patients incurred drug, other medical and lost worker
productivity costs. Patients on NZ incurred additional costs for
monitoring, diagnosis, and treatment of progressive multifocal
leukoencephalopathy (PML), a possible serious adverse event for
patients on NZ. Utility weights for each health-state were taken
from published utility assessments for people with RRMS. The
primary outcomes of the model were lifetime costs and quality-
adjusted life years (QALYs). Costs (2005US$) and outcomes
were discounted at 3% annually. RESULTS: The lifetime costs
per patient for GA were $430,242 and for NZ were $498,728.
QALYs during the lifetime of a patient on GA were 9.303 and
9.300 for a patient on NZ. The incremental cost per QALY for
patients on GA and NZ compared to symptomatic treatment
alone was $208,879 and $525,463 respectively. GA is cost-
saving when compared to NZ. PML had very little impact on
results. CONCLUSIONS: While incorporating all the long-term
clinical evidence, model results indicated that GA was both less
costly and more effective over a patient’s lifetime than NZ in
treating RRMS.
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IMMUNIZATION PROGRAM IN PARAGUAY: SOCIAL AND
BEHAVIORAL DETERMINANTS AND ORGANIZATIONAL
IMPACT
Maceira DA
Center for the Study of the State and Society, Buenos Aires,
Argentina
OBJECTIVES: Public health care system in Paraguay is highly
centralized, compared to other Latin American sectors, and more
than half of the population relies on it in order to receive formal
treatment. The National Immunization Program (EPI) is not an
exemption, affecting the way local/departmental resources in
immunization are allocated, impacting on the effectiveness of
these investments. In addition, differences in population charac-
teristics among departments, in terms of health care behavior,
income and education, and the use of formal medicine patterns
by original ethnic groups might affect EPIxs effectiveness. The
goal of the paper is to identify how supply side characteristics
(ﬁnancial, managerial and immunization strategies) and demand
side factors impact on immunization coverage. METHODS: The
document proposes a sequential model, where local health
authorities intent to ﬁll the gap in immunization ﬁnancing and
managerial needs, based on the resources allocation and coverage
strategy deﬁned by the national health ministry, that leads the
Paraguayan immunization design. As a result, a logistic model
was implemented, where the likelihood of being vaccinated is
tested as a dependent variable, where geographical, educational
and ethnical barriers are checked. In addition, supply variables
related to ﬁnancing, coverage strategies and communicational
efforts are included. The study analyze data from the Integrated
National Household Survey (2001), complemented with a series
of immunization effectiveness indexes constructed based on man-
agement, ﬁnancing and vaccine provision criterion, distinguish-
ing among ﬁnancial sustainability, management effectiveness and
antigen supply volatility, collected from ofﬁcial sources and inter-
views with key personnel by region. RESULTS: Health care
policy variables were statistically signiﬁcant, showing the rel-
evance of social communication, measured in terms of physical,
monetary and human resources involved. CONCLUSION: The
paper shows the importance of socio-economic-cultural barriers
on the probability of being immunized, based on health behavior,
presence of formal health insurance, and main source of care
(hospital, traditional medicine, etc.).
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THE GENERIC COST-EFFECTIVENESS OF HEALTH CARE
Meerding WJ, Mackenbach J
Erasmus MC, Rotterdam,The Netherlands
OBJECTIVES: To assess the generic cost-effectiveness of health
care. METHODS: We estimated the contribution of prevention
and medical care towards population health for infectious dis-
eases, cancers, and cardiovascular diseases. This contribution
was deﬁned as the difference between the current burden of
disease (BoD) and its counterfactual: a ‘null’ situation without
selected prevention (vaccinations, screening, and preventive
medication) and medical care, and accounting for the role of
other health determinants such as improvements in housing and
nutrition, and reduced smoking. The counterfactual was back-
calculated with use of historical data on incidence, survival,
mortality, and the prevalence of risk factors. The Global Burden
of Disease methodology was applied, combining incidence,
prevalence, mortality, and disability weights into multi-state
lifetables. If required, epidemiological estimates were made
internally consistent with advanced modelling techniques
(DISMOD2). The difference between the current BoD and the
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